| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 07/22/2009 | CN100515494C Immunisation against chlamydia trachomatis |
| 07/22/2009 | CN100515427C self emulsifying soft capsule of breviscapine and its preparation |
| 07/22/2009 | CN100515420C Pharmaceutical compositions of tizoxanide and nitazoxanide |
| 07/21/2009 | US7563922 catalytic chemical preparation of intermediate 4-(2-cyanoethenyl)-2,6-dimethylbenzenamine stereoisomers in presence of palladium chloride; having HIV inhibiting properties |
| 07/21/2009 | US7563881 Nucleic acid encoding polypeptide involved in cellular entrance of the PRRS virus |
| 07/21/2009 | US7563876 For binding and blocking human mannose receptors; fibronectins; immunoglobulins; cd antigens; cytolysis; cytotoxic lymphocytes; for treatment of automimmune diseases |
| 07/21/2009 | US7563792 Biguanide and dihydrotriazine derivatives |
| 07/21/2009 | US7563790 Pyridazine derivatives |
| 07/21/2009 | US7563788 3-[2-(3-Ethyl-ureido)-7-pyridin-3-yl-imidazo[1,2-a]pyridin-5-yl]-[1,2,4]oxadiazole-5-carboxylic acid methylamide; antibiotic resistance; grampositive, gramnegative, anaerobic bacteria; otitis; sinusitis, pharyngitis/tonsilitis, bronchitis, urinary tract infections, skin infections, pneumonia, septicemia |
| 07/21/2009 | US7563784 substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation |
| 07/21/2009 | US7563778 Antisense oligonucleotide preparation method |
| 07/21/2009 | US7563593 Harvesting, separating, culturing and exposing tissue to antiproliferative agents, monitoring variation in tissue propagation; immunotherapeutics; wound healing agents |
| 07/21/2009 | US7563466 Antiinflammatory agents for both viral and non-viral lesions |
| 07/21/2009 | US7563450 UL16 binding protein 4 |
| 07/21/2009 | US7563449 Methods for reducing cattle reproductive diseases |
| 07/21/2009 | CA2380481C Process for preparing a charcoal-gm1 complex |
| 07/21/2009 | CA2379972C Prodrug of an ice inhibitor |
| 07/21/2009 | CA2328528C Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| 07/16/2009 | WO2009089534A2 Compositions and methods for the treatment of viral infections caused by influenza virus |
| 07/16/2009 | WO2009089361A2 Systems methods and formulation for topically treating nail fungal infection and nail psoriasis |
| 07/16/2009 | WO2009089147A2 Methods and compositions for the treatment of cancers and pathogenic infections |
| 07/16/2009 | WO2009089121A2 Hemagglutinin polypeptides, and reagents and methods relating thereto |
| 07/16/2009 | WO2009089070A2 Compositions and methods for reducing particle penetration through mucus |
| 07/16/2009 | WO2009088719A1 Inhibitors of cytochrome p450 |
| 07/16/2009 | WO2009088042A1 Atomizing agent for prevention of infection with influenza virus |
| 07/16/2009 | WO2009088032A1 Antibody directed against pcrv |
| 07/16/2009 | WO2009087622A2 Sldlr in viral hepatitis |
| 07/16/2009 | WO2009087474A2 Agonists for antimicrobial peptide systems |
| 07/16/2009 | WO2009087238A2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies |
| 07/16/2009 | WO2009087153A1 Tricyclic nitrogen compounds and their use as antibacterial agents |
| 07/16/2009 | WO2009087151A1 Polymorphic forms of moxifloxacin hydrochloride and processes for preparation thereof |
| 07/16/2009 | WO2009087110A1 Secretable hiv entry inhibitory peptides for therapy of hiv infection |
| 07/16/2009 | WO2009086656A1 Y-type polyethylene glycol modified g-csf and preparation method and use thereof |
| 07/16/2009 | WO2009067166A3 Non-nucleoside reverse transcriptase inhibitors |
| 07/16/2009 | WO2009056535A3 Methods and kits for inducing a ctl response using a prime boost regimen |
| 07/16/2009 | WO2009046860A3 Use of dago as a therapeutic agent |
| 07/16/2009 | WO2009046859A3 Use of af12198 and dago as therapeutic agents |
| 07/16/2009 | WO2009040035A3 Use of a peptide as a therapeutic agent |
| 07/16/2009 | WO2009039990A3 Use of icam peptide as a therapeutic agent |
| 07/16/2009 | WO2009039974A3 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 07/16/2009 | WO2009033817A3 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 07/16/2009 | WO2009033766A3 Use of a peptide as a therapeutic agent |
| 07/16/2009 | WO2009020481A3 Therapeutic compositions and methods for treating gram-negative bacterial infections |
| 07/16/2009 | WO2009009759A3 Yersinia pestis antigens, vaccine compositions, and related methods |
| 07/16/2009 | WO2008114037A8 Treatment of inflammation and/or endotoxic shock |
| 07/16/2009 | WO2008079464A8 Stable powder formulations of alum-adsorbed vaccines |
| 07/16/2009 | WO2008040111A8 Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| 07/16/2009 | WO2007118329A8 Methods and agents for treating tuberculosis |
| 07/16/2009 | US20090182129 Capsular Polysaccharide Solubilisation and Combination Vaccines |
| 07/16/2009 | US20090182128 Capsular Polysaccharide Solubilisation and Combination Vaccines |
| 07/16/2009 | US20090182056 Pharmaceutical formulations of amyloid inhibiting compounds |
| 07/16/2009 | US20090182055 Fungicidal agent containing n-chlorotaurine and use thereof |
| 07/16/2009 | US20090182027 Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| 07/16/2009 | US20090182006 Treating a respiratory disorder by administering a hydrate of Gemifloxacinwith a carrier or excipient; chemical resistance; humidity; storage stability; thermodynamics; materials handling; sksin disorders; soft tissue-targeted therapy; sexual disorders; bovine mastitis; veterinary medicine |
| 07/16/2009 | US20090181996 Substituted quinolones iii |
| 07/16/2009 | US20090181993 Hiv inhibiting 5-heterocyclyl pyrimidines |
| 07/16/2009 | US20090181989 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer |
| 07/16/2009 | US20090181985 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND |
| 07/16/2009 | US20090181982 Substituted pyrroline kinase inhibitors |
| 07/16/2009 | US20090181972 Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications |
| 07/16/2009 | US20090181959 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| 07/16/2009 | US20090181955 Antibacterial Agents |
| 07/16/2009 | US20090181949 1h-imidazole derivative having cb1, agonistic, cb1 partial agonistic or cb1 antagnistic activity |
| 07/16/2009 | US20090181940 Imidazopyrazine Tyrosine Kinase Inhibitors |
| 07/16/2009 | US20090181931 Antiviral activity of cidofovir against oncolytic viruses |
| 07/16/2009 | US20090181921 2-5a analogs and their methods of use |
| 07/16/2009 | US20090181902 Modulators of pharmacokinetic properties of therapeutics |
| 07/16/2009 | US20090181889 Compositions and methods for detection and treatment of human herpesvirus (hhv)-6 |
| 07/16/2009 | US20090181106 Compositions and methods for treating vaginal infections and pathogenic vaginal biofilms |
| 07/16/2009 | US20090181101 Nanoparticles comprising antibacterial ligands |
| 07/16/2009 | US20090181100 Dry powder aerosols of Nanoparticulate drugs |
| 07/16/2009 | US20090181081 Systemic Treatment of Pathological Conditions Resulting From Oxidative Stress and/or Redox Imbalance |
| 07/16/2009 | US20090181069 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| 07/16/2009 | US20090181055 Gallibacterium anatis isolate BIV-07990 deposited with ATCC under accession number ATCC No.PTA-3669; beta( beta )-haemolysis-positive, Gram-negative, oxidase-positive, catalase-positive, urease-negative, nitrate-positive and indole-negative; for treatment of respiratory diseases in poultry |
| 07/16/2009 | US20090181053 Capsular polysaccharide solubilisation and combination vaccines |
| 07/16/2009 | US20090181052 Vaccine |
| 07/16/2009 | US20090181050 Manufacturing Method of Combined Vaccine |
| 07/16/2009 | US20090181049 Capsular polysaccharide solubilisation and combination vaccines |
| 07/16/2009 | US20090181042 Novel peptides of the respiratory syncytial virus (RSV) G protein and their use in a vaccine |
| 07/16/2009 | US20090181040 Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 07/16/2009 | US20090181036 Pharmaceutical Compositions and Articles of Manufacture Useful in Reversal of a Clinical Episode of an Incurable Disease and Methods of Use Thereof |
| 07/16/2009 | US20090180996 Epigenetic modification of cell phenotype, fate and/or function by RNA transfer |
| 07/16/2009 | US20090180985 Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors |
| 07/16/2009 | US20090180983 Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
| 07/16/2009 | US20090180981 Quinoxalinyl derivatives |
| 07/16/2009 | US20090180980 Anti-Arenaviral Compunds |
| 07/16/2009 | CA2711863A1 Antibody directed against pcrv |
| 07/16/2009 | CA2711807A1 Agonists for antimicrobial peptide systems |
| 07/16/2009 | CA2711652A1 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies |
| 07/16/2009 | CA2711334A1 Hemagglutinin polypeptides, and reagents and methods relating thereto |
| 07/16/2009 | CA2711217A1 Antimicrobial compositions |
| 07/16/2009 | CA2710841A1 Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof |
| 07/16/2009 | CA2710679A1 Inhibitors of cytochrome p450 |
| 07/16/2009 | CA2710664A1 Sldlr in viral hepatitis |
| 07/16/2009 | CA2702992A1 Methods of inhibiting bacterial virulence and compounds relating thereto |
| 07/15/2009 | EP2078726A1 Secretable HIV entry inhibitory peptides for therapy of HIV infection |
| 07/15/2009 | EP2078718A1 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof |
| 07/15/2009 | EP2078713A1 Inhibitors of biofilm formation of gram-positive and gram-negative bacteria |
| 07/15/2009 | EP2078527A1 Aqueous liquid preparation comprising gatifloxacin |
| 07/15/2009 | EP2078526A1 Aqueous liquid preparation having improved intraocular gatifloxacin penetration |